Register now!
Prostate Cancer Academy is an expert-led
webinar series on mCRPC-related topics
This virtual, four-part webinar series includes:
Interactive
educational sessions
CPD-certified
learning
Learning from
expert speakers
This link will take you to a promotional website where AZ/MSD products will be mentioned.
This is a promotional event organised and funded by MSD and AstraZeneca for UK healthcare professionals only. MSD/AstraZeneca products will be discussed at this meeting.
Please consult the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.
Click here for UK Prescribing Information
LYNPARZA (olaparib) tablets are indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.1
LYNPARZA tablets are indicated as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic)
who have progressed following prior therapy that included a new hormonal agent.1
https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to AstraZeneca (UK) by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033.
